Majhail Navneet S, Brunstein Claudio G, Wagner John E
Department of Medicine, Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA.
Curr Opin Immunol. 2006 Oct;18(5):571-5. doi: 10.1016/j.coi.2006.07.015. Epub 2006 Aug 8.
Unrelated umbilical cord blood (UCB) is an alternative donor source for allogeneic haematopoietic cell transplantation and, compared with unrelated donor bone marrow, has the advantages of rapid availability, greater tolerance of HLA disparity and lower incidence of severe graft-versus-host disease. Graft cell dose is an important determinant of haematopoietic recovery and overall outcome following UCB transplantation, and the limited cell dose of single UCB units has been a major barrier to its more widespread use. Transplantation with two unrelated UCB units is feasible, safe and effective and can overcome the limitation of cell dose of single UCB units.
非亲属脐带血（UCB）是异基因造血细胞移植的另一种供体来源，与非亲属供体骨髓相比，具有可快速获取、对HLA差异耐受性更高以及严重移植物抗宿主病发生率更低的优点。移植物细胞剂量是脐带血移植后造血恢复和总体结局的重要决定因素，单个脐带血单位的细胞剂量有限一直是其更广泛应用的主要障碍。使用两个非亲属脐带血单位进行移植是可行、安全且有效的，并且可以克服单个脐带血单位细胞剂量的限制。
